Osim is an FDA‐approved drug for the treatment of NSCLC harboring activating EGFR mutations (first‐line) or that has become resistant to 1‐st generation EGFR‐TKIs through the T790M mutation (second‐line). Here, EGFR is linked to non-small cell lung carcinoma.